NORTH CHICAGO, Ill., June 11, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a four-year follow-up analysis of the Phase 3 CLL14 trial, which showed that previously untreated patients with chronic lymphocytic leukemia (CLL) with coexisting conditions who were treated with VENCLYXTO^®/VENCLEXTA^® (venetoclax) plus obinutuzumab continued to show longer progression-free survival (PFS) and higher rates of undetectable minimal residual disease (MRD) compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil. The data were presented for the first time today during the virtual 26^th European Hematology Association (EHA) Annual Congress (abstract #S146).

IRVINE, Calif., June 8, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is changing the way BOTOX^® Cosmetic, the #1 selling neurotoxin treatment¹, is connecting with consumers. Today, the brand is launching 'See Yourself', a new campaign featuring documentary style shorts that dive deep into the stories of real BOTOX^® Cosmetic patients - people of all shapes, sizes, backgrounds, colors, and origins. BOTOX^® Cosmetic is the first brand in the category to focus on the unique journeys of its consumers, aiming to create greater transparency and a judgement-free dialogue around the decision to choose an aesthetic treatment for yourself.

NORTH CHICAGO, Ill., June 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) study investigating IMBRUVICA^® (ibrutinib) in combination with VENCLEXTA^®/VENCLYXTO^® (venetoclax), an all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination, for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) during an oral presentation at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7501). The ibrutinib and venetoclax cohort met its primary endpoint of complete response (CR) rate of 56% (95% CI 48-64) among patients without del(17p), 70 years old or younger and with 27.9 months of follow up. This rate was higher than the 37% minimum meaningful rate study assumption (P<0.0001). The CR rate was consistent across all patients in the study including high-risk CLL patient groups. Furthermore, 24-month progression free survival (PFS) and overall survival (OS) were 95% and 98%, respectively. 

NORTH CHICAGO, Ill., June 4, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced extended long-term data from the Phase 3 RESONATE-2 study (PCYC-1115/1116) evaluating single-agent IMBRUVICA (ibrutinib) versus chlorambucil with up to seven years of follow-up in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).¹ These data will be presented on June 4^th during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7523). Additionally, new data will be presented during the European Hematology Association (EHA) Virtual Congress from June 9-17, including findings from the informCLL™ real-world prospective observational registry assessing how real-world treatment patterns align with National Comprehensive Cancer Network (NCCN^®)-recommended regimens for CLL/SLL.

NORTH CHICAGO, Ill., June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 42^nd Annual Global Healthcare Conference on Tuesday, June 8, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present virtually at 8:40 a.m. Central time.

NORTH CHICAGO, Ill., June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing risankizumab 360 mg (subcutaneous [SC]; administered every eight weeks) achieved the co-primary endpoints of endoscopic response and clinical remission at one year in adult patients with moderate to severe Crohn's disease.¹

NORTH CHICAGO, Ill., June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with RINVOQ^® (upadacitinib, 15 mg, once daily) resulted in sustained improvements in disease activity for more than one year (56 weeks) among patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs (bDMARDs).¹ At week 56, 29 percent of patients treated with continuous RINVOQ 15 mg achieved minimal disease activity^a (MDA).¹ Results at week 56 were not multiplicity controlled.¹ The full, long-term results from the Phase 3 SELECT-PsA 2 clinical trial will be presented at the EULAR 2021 Virtual Congress. These results were also recently published online in Rheumatology and Therapy in April 2021.⁴

NORTH CHICAGO, Ill., June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new analyses to be presented at the EULAR 2021 Virtual Congress showing patients with moderate to severe rheumatoid arthritis on background methotrexate (MTX) treated with RINVOQ^® (upadacitinib, 15 mg, once daily) maintained higher rates of clinical remission and low disease activity through three years compared to those patients treated with HUMIRA^® (adalimumab).¹ Additionally, a separate integrated safety analysis found the safety profile of RINVOQ was consistent over 4.5 years, with no new safety risks observed.²

NORTH CHICAGO, Ill., May 26, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in Bernstein's 37^th Annual Strategic Decisions Conference on Wednesday, June 2, 2021. Michael Severino, M.D., vice chairman and president, and Robert A. Michael, executive vice president and chief financial officer, will present virtually at 2:30 p.m. Central time.

NORTH CHICAGO, Ill., May 26, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from its migraine portfolio will be presented at the 2021 American Headache Society (AHS) Annual Scientific Meeting, to be held virtually June 3-6. A total of 23 abstracts, including four podium presentations, will be shared from a broad range of studies across AbbVie's migraine portfolio.